Poster

Moving Towards A Closed CAR T Cell Manufacturing Process

Source: Cytiva

By Devina Ramsaroop, Steven Loo Yong Kee, Danylo Sirskyj, Calley Hirsch, Elizabeth Csaszar, and Aaron Dulgar Tulloch

CAR T therapy shows great promise for treating hematologic malignancies, and there is a growing need for bioprocess workflow solutions supporting industrial scale up and scale out of these therapies Challenges. Challenges to overcome in the CAR T manufacturing process include lengthy production times (11 - 21 days), product variability associated with open handling steps, and high manufacturing costs Here we examine and evaluate individual CAR T cell unit operations, commercial reagents, and equipment with process closure potential to develop an improved workflow and increase product consistency.

  • Identify commercially available reagents that enhance process efficiency
  • Identify and evaluate equipment to reduce manual manipulation time
  • Integrate automation strategies to reduce open operations

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: